Did Phibro Animal Health beat or miss consensus estimates last quarter?

What does Phibro Animal Health do and what are its main business segments?

What factors drove the changes in Phibro Animal Health's revenue and profit?

What is Phibro Animal Health's latest dividend and current dividend yield?

What is the market's earnings forecast for Phibro Animal Health next quarter?

What were the key takeaways from Phibro Animal Health's earnings call?

What is the revenue and EPS growth rate for Phibro Animal Health year over year?

What is Phibro Animal Health's gross profit margin?

- **Revenue Growth**: Q2 sales $373.9M (+21% YoY); FY2026 guidance raised to $1.45B-$1.5B.
- **Profit Expansion**: Adjusted EBITDA $89.4M (+41%); FY2026 target $245M-$255M (+33%-39%).
- **Leadership Transition**: Donny Bendheim to lead with Phibro Forward strategy, emphasizing R&D and sustainability.
- **Gross Margin Drivers**: Price hikes, mix shifts, and one-time inventory timing benefits (+60% net income growth).
- **Market Momentum**: Protein demand resilience, customer confidence, and technical support differentiation.

**【Management Opening Remarks】**
- CFO Glenn David introduced the call, highlighting Q2 FY2026 results and updated FY2026 guidance. He emphasized the webcast availability and key financial metrics, including GAAP and non-GAAP reconciliations.

**【CEO Commentary】**
- Jack Bendheim reported 26% Animal Health sales growth and 41% EBITDA increase, driven by MFA integration success. He highlighted strong performance in Medicated Feed Additives (34% growth), nutritional specialties (9%), and vaccines (13%). Customer feedback from Barcelona and IPPE events underscored operational alignment and market optimism.
- CEO praised leadership unity and customer enthusiasm for MFA technical support, signaling sustainable momentum.

**【Leadership Transition】**
- Daniel Bendheim (Donny) announced his CEO transition, emphasizing stability with Jack Bendheim as Executive Chairman. He highlighted Phibro Forward strategy focus on R&D, digital capabilities, and sustainability-linked profitability. Donny stressed the competitive advantage of retained management continuity.

**【CFO Financial Commentary】**
- Q2 net sales: $373.9M (+21% YoY). Animal Health: $290M (+26%); Minerals: $68.9M (+9%); Performance Products: $15M (-10%).
- Adjusted EBITDA: $89.4M (+41%); Adjusted net income: $30.8M (+60%).
- Gross margin improvements from price hikes (Zoetis portfolio), mix shifts (nutritional specialties), and one-time $10M inventory timing benefit.
- Updated FY2026 guidance: Sales $1.45B-$1.5B (+12%-16%), EBITDA $245M-$255M (+33%-39%), Net Income $120M-$127M (+41%-49%).

**【Q&A Highlights】**
- **Gross Margin Drivers**: Price increases (+Zoetis), mix (high-margin products), one-time inventory timing. Expect sustained margin expansion with Phibro Forward.
- **MFA Timing Impact**: $10M legacy MFA decline due to customer inventory pullback; expected recovery in Q3/Q4.
- **Market Sustainability**: Favorable feed costs, protein demand resilience, and geographic diversification support growth.
- **Share Gains**: Poultry anticoccidials and swine rhinitis products outperforming peers.
- **Phibro Forward**: Structural cost savings and R&D investments to accelerate in FY2027.
- **Companion Animal**: Restoris launch gaining traction; future innovations (oral health) to contribute post-FY2026.

Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript

- **Revenue Surge**: Q1 2026 net sales up 40% to $363.9M, with Animal Health segment growing 55%.
- **MFA Dominance**: Medicated Feed Additives (MFA) sales jumped 81%, driving 85% EBITDA growth.
- **Companion Innovation**: Launch of Restoris dental gel and licensed therapeutic compound to address unmet companion animal needs.
- **Financial Health**: Adjusted EBITDA $102.7M (+102%), with FY26E guidance for 28% EBITDA growth.
- **Strategic Expansion**: Companion animal focus via dental care solutions, leveraging protein demand trends.


**【CEO Opening Remarks】**
- **Strong Q1 Performance**: Animal Health segment revenue grew 55% YoY, driven by 81% growth in Medicated Feed Additives (MFA) and 25% increase in vaccines.
- **Integration Success**: Seamless integration of the acquired MFA portfolio, with legacy business contributing 11% growth.
- **Consumer Trends**: Research shows GLP-1 users are shifting to high-quality proteins, supporting long-term demand for animal health products.
- **Innovation**: Launch of Restoris dental gel and a licensed therapeutic compound for companion animals, signaling expansion into companion care.

**【CFO Financial Highlights】**
- **Topline Growth**: Q1 net sales $363.9M (+40% YoY), with Animal Health segment at $283.5M (+55% YoY).
- **Profitability**: Adjusted EBITDA $102.7M (+102% YoY), driven by MFA, vaccines, and cost control.
- **Segment Breakdown**: MFA & Other (+81%), Nutritional Specialties (+13%), Vaccines (+25%).
- **Guidance**: FY26E sales $1.425B-$1.475B, EBITDA $230M-$240M, reflecting 28% growth.
- **Leverage**: Gross leverage 3.3x, net leverage 2.9x, with $85M cash on hand.

**【Q&A Highlights】**
- **Sustainability of Growth**: Legacy MFA demand driven by protein consumption trends, with no material one-time items.
- **Margin Dynamics**: Q1 margin favorability from high-margin products, but expect slight decline due to Restoris investments.
- **Companion Animal Strategy**: Dental care as unmet need; Restoris enables non-surgical treatment, freeing up vet capacity for high-value procedures.
- **Market Position**: Strong presence in key livestock markets, complemented by MFA acquisition in Asia and Europe.
- **R&D Focus**: Targeting innovation gaps in companion animals, avoiding direct competition with big 4 players.


Phibro Animal Health Corporation (PAHC) Q1 2026 Earnings Call Transcript

- **Revenue Growth**: FY2025 Animal Health sales up 36% to $962.8M; FY2026 guidance projects 10%-14% net sales growth ($1.425B-$1.475B). Zoetis MFA contributes $208M in FY2025, expected to drive $40M-$50M EBITDA in FY2026.
- **Profit Expansion**: Adjusted EBITDA up 65% YoY to $297.5M in FY2025; FY2026 target of $225M-$235M (+22%-28%). Adjusted EPS grows 44% YoY to $3.00 in FY2025, guided to $2.52-$2.70 in FY2026.
- **Strategic Momentum**: Phibro Forward initiatives to peak in FY2027, with FY2026 one-time costs (~$10M). Zoetis MFA integration 90% complete, with full independence by Q4 2025. Legacy MFA outpaces industry (+7% YoY).

**【CEO Summary Section】**
- **Q4 2025 Highlights**: Animal Health segment grew 53% (sales $292.7M), driven by 77% growth in MFA and other (Zoetis integration). Vaccines and Nutritional Specialties rose 21% and 11%, respectively. Full-year Animal Health sales increased 36% to $962.8M, with MFA and other up 54%.
- **FY2026 Guidance**: Net sales $1.425B-$1.475B (10%-14% growth), adjusted EBITDA $225M-$235M (22%-28% growth), adjusted EPS $2.52-$2.70. Growth fueled by Zoetis MFA (full 12 months vs. 8 months in FY2025) and Phibro Forward initiatives.
- **Strategic Focus**: Scaling operations, global footprint expansion, and innovation pipeline. Phibro Forward expected to peak in FY2027, contributing to long-term margin improvement.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Consolidated net sales $378.7M (+39% YoY), adjusted EBITDA $105.1M (+49% YoY), adjusted EPS $1.08 (+39% YoY). Animal Health adjusted EBITDA $60.6M (+47% YoY), driven by MFA and cost control.
- **FY2025 Financials**: Net sales $1.296B (+27% YoY), adjusted EBITDA $297.5M (+65% YoY), adjusted EPS $3.00 (+44% YoY). Free cash flow $43M, gross leverage 3.1x, net leverage 2.8x.
- **Phibro Forward Impact**: FY2026 guidance includes $40M-$50M EBITDA contribution from Zoetis MFA and legacy business growth. One-time costs (~$10M) for strategic initiatives.

**【Q&A Key Highlights】**
- **Organic Growth Assumptions**: Legacy MFA expected to grow flat to low single digits; vaccines and Nutritional Specialties to stabilize but remain strong. FY2026 guidance assumes 12 months of Zoetis MFA vs. 8 months in FY2025.
- **Phibro Forward Details**: Low-hanging fruit includes price increases, expanded product offerings, and procurement savings. Strategic investments focus on global expansion, innovation, and customer engagement (e.g., CRM, churn desk).
- **Zoetis Integration Progress**: 90% of MFA revenue operating independently; full transition by Q4 2025 calendar year. Tariffs included in guidance, but major shifts not accounted for.
- **Market Outlook**: Brazil tariffs and US cattle segment expansion opportunities. Legacy Animal Health outperformed industry (+7% vs. flat/lower single-digit growth).

Phibro Animal Health Corporation (PAHC) Q4 2025 Earnings Conference Call Transcript

- **Revenue Surge**: 32% YoY growth driven by MFA acquisition and operational efficiency.
- **Profit Expansion**: EBITDA up 85%, EPS doubles, with strong cash flow generation.
- **Tariff Resilience**: $5-10M FY2026 impact manageable via domestic sourcing and price adjustments.
- **Strategic Momentum**: Phibro Forward poised to deliver $5M+ annual savings and full MFA portfolio contribution in FY2026.

**【CEO Opening Remarks】**
- **Q3 2025 Highlights**: Total sales up 32% YoY to $347.8M, adjusted EBITDA rose 85% to $63.1M, and adjusted EPS doubled to $1.08.
- **Segment Performance**: 
  - Animal Health (+42%): New MFA business contributed $77M, legacy MFA sales declined 3% due to order timing.
  - Nutritional Specialties (+8%): Microbial and companion animal products drove growth.
  - Performance Products (+28%): Personal care ingredient demand surged.
- **Strategic Initiatives**: Phibro Forward focuses on operational excellence, with $5-10M tariff mitigation plans for FY2026.
- **Guidance Update**: Narrowed FY2025 ranges to $1.26-1.29B net sales, $177-183M EBITDA, and $1.96-2.09 EPS (midpoint +70%).

**【CFO Financial Breakdown】**
- **GAAP Results**: Net income $42.4M, EPS $0.62, driven by MFA integration and cost control.
- **Adjusted Metrics**: EBITDA $63.1M (+73%), gross margin improved due to mix and lower input costs.
- **Cash Flow**: $49M free cash flow (12M trailing), $70M cash on hand, 3.0x gross leverage.
- **Debt Management**: Fixed-rate swaps for $150M (3.18%) and $275M (3.64%), collar for $250M (4.75% cap).

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: 80%+ inputs sourced domestically; price hikes and supplier renegotiations offset $5-10M FY2026 impact.
- **MFA Growth**: Year-to-date +7% despite Q3 decline; long-term demand supported by livestock expansion.
- **Forward Strategy**: $5M+ annual savings from procurement, supply chain, and pricing initiatives.
- **FX Impact**: Minimal due to USD pricing in international markets.


Phibro Animal Health Corporation (PAHC) Q3 2025 Earnings Call Transcript

- **Record Growth**: Q2 revenue up 24% to $309M, with 47% jump in Animal Health (Zoetis MFA +11% legacy growth). Adjusted EBITDA +64% to $106M.
- **MFA Synergy**: $37M Q2 contribution vs. $200M annual target, 90%+ customer retention, and $0.25+ EPS upside.
- **Margin Expansion**: Gross margin +11pts, FY2025 EBITDA margin guidance at 13.8-14.4% (vs. 9.2% 2024).
- **Tariff Resilience**: Minimal direct impact; China plant operations unaffected, with mitigation plans for cost pass-through.
- **Strategic Focus**: Livestock growth (75% revenue) outpaces companion animals, with 30+ new product launches in pipeline.


**【CEO Opening Remarks】**
- Q2 2025 revenue reached $309.3M, up 24% YoY, driven by 47% growth in the Animal Health segment (including $36.7M from Zoetis MFA in 2 months). Adjusted EBITDA surged 64% to $105.8M.
- Zoetis MFA integration seamless, with December sales doubling November due to transition stabilization. Legacy business saw 11-12% growth across MFA, vaccines, and nutritional specialties.
- Fiscal 2025 guidance updated to $1.25B-$1.3B net sales (23-28% growth) and $172M-$180M adjusted EBITDA (55-62% growth), reflecting confidence in legacy + MFA synergy.

**【CFO Financial Breakdown】**
- GAAP net income: $52.3M (vs. $23.0M YoY), driven by MFA contribution and 11% gross margin expansion. Adjusted EPS: $1.08 (vs. $0.55 YoY).
- Free cash flow: $15M (12M trailing), with $67M cash on hand. Leverage ratio: 3.1x (GAAP) and 2.9x (net debt/EBITDA).
- FY2025 diluted EPS guidance: $1.87-$2.01 (57-69% growth), including $0.25+ from MFA and legacy margin improvements.

**【Q&A Highlights】**
- **MFA Integration**: 90%+ customer retention, $37M Q2 contribution vs. $200M annual target. System transitions and regulatory approvals on track.
- **Tariff Impact**: Minimal direct exposure; China plant operations unaffected. Mitigation plans in place for cost pass-through.
- **Demand Trends**: Global protein sector strong, with poultry, swine, and cattle markets driving 11-12% legacy growth. Avian influenza risks managed via biosecurity solutions.
- **Companion Animal Strategy**: Pipeline expansion continues, but livestock (75% revenue) remains focus with 30+ new product launches in pipeline.
- **Phibro Forward Initiative**: $10M+ annual savings via procurement, pricing, and efficiency gains, offset by $3M one-time consulting costs.


Actual												0.38	0.17	0.27	0.34	0.34	0.32	0.25	0.37	0.33	0.36	0.21	0.34	0.29	0.38	0.14	0.33	0.31	0.41	0.35	0.54	0.63	0.57	0.73	0.87
Forecast												0.34	0.23	0.2014	0.28	0.348	0.3125	0.2933	0.3277	0.3533	0.3767	0.2633	0.3025	0.335	0.3725	0.23	0.28	0.29	0.3333	0.248	0.425	0.5205	0.5213	0.6225	0.67
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+11.76%	-26.09%	+34.06%	+21.43%	-2.30%	+2.40%	-14.76%	+12.91%	-6.59%	-4.43%	-20.24%	+12.40%	-13.43%	+2.01%	-39.13%	+17.86%	+6.90%	+23.01%	+41.13%	+27.06%	+21.04%	+9.34%	+17.27%	+29.85%

PAHC

PAHC fundamentals

PAHC Q2 2026 Earnings

Earnings Call

You can ask Aime

PAHC

PAHC fundamentals

PAHC Q2 2026 Earnings

Earnings Call

PAHC Earnings Call Summary for Q2/20269:00 AM on Feb 5, 2026

PAHC Earnings Call Summary for Q1/20269:00 AM on Nov 6, 2025

PAHC Earnings Call Summary for Q4/20259:00 AM on Aug 28, 2025

PAHC Earnings Call Summary for Q3/20259:00 AM on May 8, 2025

PAHC Earnings Call Summary for Q2/20259:00 AM on Feb 6, 2025

You can ask Aime